C—Side by side
Compare
Up to four peptides. Opinion rows are labeled. Copy the URL to share.
| Field | BPC-157 | TB-500 | KPV | GHK-Cu |
|---|---|---|---|---|
| Type | Research Only | Research Only | Research Only | Cosmetic / Supplement |
| Regulatory status | Not FDA-approved; no verified marketing authorization | Not FDA-approved; no verified marketing authorization | Not FDA-approved; no verified marketing authorization | Cosmetic ingredient; not FDA-approved as a drug |
| Compounding status | Off Category 2, review pending | Off Category 2, review pending | Off Category 2, review pending | Off Category 2, review pending |
| FDA-approved indications | None | None | None | None |
| Categories | Healing & repair, GI | Healing & repair | GI, Healing & repair | Skin & cosmetic, Longevity & mitochondrial |
| Claimed uses |
|
|
|
|
| Mechanism | Synthetic pentadecapeptide studied for tissue repair, angiogenesis and nitric-oxide signaling. Proposed mechanisms largely derive from animal and cell experiments. | The LKKTETQ fragment is associated with thymosin beta-4 actin-binding biology. Tissue-repair claims often extrapolate from the full-length protein rather than establish fragment efficacy. | Lys-Pro-Val is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. In cell and mouse models, PepT1-mediated uptake inhibits inflammatory NF-kappaB and MAPK signaling. | A copper-binding tripeptide investigated for extracellular-matrix remodeling, collagen production and wound-repair signaling. Much of the broad regenerative mechanism literature is preclinical. |
| Evidence level | Animal studies mostly | Animal studies mostly | Animal studies mostly | Small/early human studies |
| Evidence / Hype (opinion) | Evidence Hype | Evidence Hype | Evidence Hype | Evidence Hype |
| Momentum (opinion) | Rising | Watch | Rising | Rising |
| Routes | Injection, Oral | Injection | Oral, Topical | Topical, Injection |
| WADA | Prohibited | Prohibited | Verify | Verify |
| Where it stands (opinion) | FDA now places BPC-157 in its withdrawn-nomination table, not the active Category 2 table; this is not compounding authorization. WADA 2026 S0 prohibits BPC-157. | FDA lists the fragment among withdrawn nominations. Full-length thymosin beta-4 trials do not validate TB-500; WADA 2026 S2.3 prohibits TB-500. | Evidence remains preclinical, including mouse colitis models. FDA moved KPV to its withdrawn-nomination table; this is not authorization for compounding. | Topical cosmetic evidence and experimental tissue-repair findings do not validate systemic use. FDA lists injectable GHK-Cu among withdrawn nominations with unresolved safety concerns. |
| Last reviewed | 2026-10-30 | 2026-10-30 | 2026-10-30 | 2026-10-30 |
| News (30d) | 3 | 1 | 0 | 1 |